Technology ID
TAB-3169
Broadly Neutralizing Antibodies Against HIV-1 Directed to the CD4 Binding Site of HIV Envelope Protein
E-Numbers
E-300-2009-0
E-300-2009-1
E-300-2009-2
E-300-2009-3
E-300-2009-4
E-300-2009-5
E-300-2009-6
E-300-2009-7
E-051-2012-0
E-051-2012-1
E-051-2012-2
E-051-2012-3
Lead Inventor
Mascola, John
Lead IC
NIAID
Co-Inventors
Wyatt, Richard
Wu, Xueling
Li, Yuxing
Hogerkorp, Carl-Magnus
Roederer, Mario
Yang, Zhi-yong
Nabel, Gary
Kwong, Peter
Zhou, Tongqing
Connors, Mark
Ofek, Gilad
Yang, Yongping
Zhu, Jiang
Shapiro, Lawrence
Schief, William
Rudicell, Rebecca
Georgiev, Ivelin
Kwon, Young Do
Zhang, Baoshan
Chauang, Gwo-yu
Shi, Wei
Chuang, Gwo-Yu
ICs
NIAID
Applications
Vaccines
Therapeutics
Research Materials
Diagnostics
Therapeutic Areas
Infectious Disease
Inhibiting the ability of HIV-1, the virus that causes AIDS, to infect cells is one approach to both prevention and treatment of HIV. Scientists at the NIAID Vaccine Research Center have isolated and characterized neutralizing antibodies (VRC01, 02, 03, and 07) that bind to the CD4 binding site of HIV-1 envelope glycoprotein gp120. These human monoclonal antibodies can potentially be used as a therapeutic to: (1) treat an HIV infection, (2) decrease and prevent HIV-transmission from mother to infant, and (3) be effectively combined with anti-retroviral drug therapy. Additionally, the antibodies can be used for detection of HIV-1 infection in biological samples, including body fluids; and tissues from biopsies, autopsies, and pathology specimens.
VRC01 has been tested in several phase I clinical trials for safety and pharmacokinetics in infants, adults, and HIV-positive adults. VRC01 is currently being evaluated in a phase II clinical trial for prevention of HIV-1 acquisition.
VRC01 has been tested in several phase I clinical trials for safety and pharmacokinetics in infants, adults, and HIV-positive adults. VRC01 is currently being evaluated in a phase II clinical trial for prevention of HIV-1 acquisition.
Commercial Applications
- Monoclonal antibodies to treat and/or diagnose HIV and/or AIDS
- Immunoassays and kits
Competitive Advantages
- Monoclonal neutralizing antibodies prevent viral entry into cells
- Monoclonal neutralizing antibodies can be used for vaccine design and to develop diagnostics for HIV-1
Licensing Contact: